Suven Life Sciences - A Value PickContract Research And Pharma Manufacturing Services (CRAMS) company Suven Life Sciences registered an increase of 181.57 per cent in net profit at Rs. 3.21 crore for the quarter ended December 2005 as compared with Rs. 1.14 crore in the previous corresponding quarter. Its total income increased by 94 per cent to Rs. 27.11 crore for the quarter from Rs. 13.95 crore during the previous corresponding quarter. EPS was Rs. 1.28 as compared with Rs. 0.46 earlier.
The revenues for the nine months stood at Rs. 63.45 crore which was 104 per cent of previous year's total revenue of Rs. 60.77 crore. The cummulative net profit up to third quarter was Rs. 6.21 crore as compared to Rs 3.20 crore in the same period last year. R&D expenses increased to Rs. 4.09 crore for the quarter as compared with Rs. 1.94 crore in the previous corresponding quarter.
The company expects to file its first Investigational New Drug (IND) in the US before the end of 2006.
0 Comments:
Post a Comment
<< Home